All In Biotech

Drug Trial Radar · NCT06190951

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma

Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 151 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

151

Actual

Start

Sep 18, 2024

Primary completion

Nov 2, 2026

Study completion Dec 9, 2030

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jan 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with cemiplimab alone. These types of immunotherapy study drugs are collectively known as immune checkpoint inhibitors. Immunotherapies are treatments that use the immune system to recognize and kill cancer cells. The study is focused on participants with a type of skin cancer known as melanoma. The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to cemiplimab in participants with high-risk, resectable melanoma. Participants will receive treatment before surgery, undergo resection, and then will have the option to continue treatment after resection. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drug(s). * How much study drug(s) is in the blood at different times. * Whether the body makes antibodies against the study drug(s) (which could make the drug less effective or could lead to side effects). Antibodies are proteins that are naturally found in the blood stream that fight infections. * How administering the study drugs might improve quality of life.

Conditions

  • Melanoma

Interventions

  • cemiplimabDrug

    Administered per the protocol

  • Fixed Dose Combination (FDC) cemiplimab+fianlimabDrug

    Or coadministration, depending on availability.

  • PlaceboDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological complete response (pCR) rate as assessed by Blinded Independent Pathological Review (BIPR)Time frame: Up to 1 year

Locations

104 sites in 8 countries. Site status is shown where the registry gives one.

  • UC San Diego

    La Jolla, California

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • Hoag Family Cancer Institute

    Newport Beach, California

  • California Pacific Medical Center Research Institute

    San Francisco, California

  • University of California San Francisco (UCSF)

    San Francisco, California

  • St John's Cancer Institute

    Santa Monica, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Hartford Hospital

    Hartford, Connecticut

  • Yale University Cancer Center

    New Haven, Connecticut

  • Emory Healthcare, Emory Clinic

    Atlanta, Georgia

  • NorthShore University HealthSystem

    Evanston, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute Brookline Avenue

    Boston, Massachusetts

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Northwell Health Cancer Institute

    Lake Success, New York

  • Duke Cancer Institute, University Hospital

    Durham, North Carolina

  • Seidman Cancer Center

    Cleveland, Ohio

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • The Ohio State University James Comprehensive Cancer Center

    Columbus, Ohio

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • University of Tennessee Medical Center

    Knoxville, Tennessee

  • UT Southwestern/Simmons Comprehensive Cancer Center

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Virginia

    Charlottesville, Virginia

  • Inova Schar Cancer Institute

    Fairfax, Virginia

  • Lismore Base Hospital

    Lismore, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Melanoma Institute of Australia

    Wollstonecraft, New South Wales, Australia

  • The Townsville Hospital

    Douglas, Queensland, Australia

  • Hervey Bay Hospital

    Hervey Bay, Queensland, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • The Queen Elizabeth Hospital

    Woodville, South Australia, Australia

  • Icon Cancer Centre Hobart

    Hobart, Tasmania, Australia

  • Eastern Health

    Box Hill, Victoria, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • One Clinical Research at Hollywood Private Hospital

    Nedlands, Western Australia, Australia

  • Medical University of Vienna

    Vienna, Austria

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.